The Differential Diagnosis of Multiple Sclerosis
JNNP 71(suppl II):ii9-ii15, Scolding, N., 2001
Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
NEJM 362:387-401, 456, Kappos, L.,et al, 2010
Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010
Differential Diagnosis of Bilateral Thalamic Lesions
Clin Neuroradiol 17:3-22, Linn,J.,et al, 2007
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Cardiac Adverse Effects Associated with Mitoxantrone (Novantrone) Therapy in Patients with MS
Neurol 59:909-913, Ghalie,R.G.,et al, 2002
Clinical Presentation of Left Atrial Cardiac Myxoma
Medicine 80:159-172, Pinede,L.,et al, 2001
Autologous Hematopoietic Stem Cell Transplantation Suppresses Gd-enhanced MRI activity in MS
Neurol 57:62-68, Mancardi,G.L.,et al, 2001
Linomide Reduces the Rate of Active Lesions in Relapsing-Remitting Multiple Sclerosis
Neurol 47:895-900, Anderson,O.,et al, 1996
Multiple Sclerosis as a Cause of Atrial Fibrillation and Electrocardiographic Changes
Arch Neurol 49:422-424, Schroth,W.S.,et al, 1992
Clinical Correlations of Periodic Lateralized Epileptiform Discharges
Clin Electroenceph 8:191-202, Porecha,H.P.&Reilly,E.L., 1977
Association of Changes in Activity Patterns with Brain Atrophy and Disability Progression in People with Multiple Sclerosis
Neurol 106:e214678, e214742, Fitzgerald,K.C.,et al, 2026
Using Susceptibility-Based Imaging in Highly Active Late-Onset Multiple Sclerosis
Neurol 106:e214794, Sosa,S.M.,et al, 2026
Paramagnetic Rim Lesions and Development of Clinical MS in Radiologically Isolated Syndrome
JAMA Neurol 83:250-258, Lim,T.R.et al, 2026
Frequency of AQP4 and MOG Antibodies in Patients with Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria
Neurol 106:e214753, Deschamps,R.,et al, 2026
The 2024 McDonld Criteria for Dignosis of Multiple Sclerosis, The Rubber meets the Road
Neurol 106:e214688, Miller, A.E., 2026
Using Susceptibility-Based Imaging in highly ctive Late-Onset Multiple Sclerosis
Neurol 106:e214794, Sosa,S.M.,et al, 2026
Progress Toward Mitigating Disability Progression in Multiple Sclerosis
NEJM 392:1966-1968, Calabresi,P.A., 2025
Frequency and Diagnostic Implications of Paramagnetic Rim Lesions in People Presenting for Diagnosis to a Multiple Sclerosis Clinic
Neurol 105:e213912, Remner,B.,et al, 2025
Diagnosis of Multiple Sclerosis: 2024 Revisions of the McDonald Criteria
Lancet Neurol 24:850-865, Montalban,X.,et al, 2025
A 30-Year-Old Female Patient with Multiple Sclerosis Presenting with Rapidly Progressive Cranial Neuropathies, Weakness, and Ataxia
Neurol 105:e214429, Trentadue,T.,et al, 2025
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Inhibition of CD40L with Frexalimab in Multiple Sclerosis
NEJM 390:589-600, 662, Vermersch,P.,et al, 2024
Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis
Ann Neurol 96:846-854, Marrodan,M.,et al, 2024
Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease
Ann Neurol 96:1086-1091, Fadda,G.,et al, 2024
Differentiating Multiple Sclerosis from AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease with Imaging
Neurol 100:e308-e323, Cortesa,R.,et al, 2023
Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder
Neurol 100:e1418-e1432, Cacciaguerra, L.,et al, 2023
Association of Very Early treatment Initiation with the Risk of Long-Term Disability in Patients with a First Demyelinating Event
Neurol 101:e1280-e1292, 549, Cobo-Calvo,A.,et al, 2023
Clinical and Radiologic Features, Pathology, and Treatment of Balo Concentric Sclerosis
Neurol 97:e414-e422, Jolliffe, E.A.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Radiologically Isolated Syndrome: A Review for Neuroradiologists
AJNR 41:1542-1549, Hosseiny, M.,et al, 2020
Paramagnetic Rim Lesions are Specific to Multiple Sclerosis:An International Multicenter 3T MRI Study
Ann Neurol 88:1034-1042, Maggi,P.,et al, 2020
Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA 32:175-187, Brown, J.W.L.,et al, 2019
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Simultaneous CMV and Listeria Infection Following Alemtuzumab Treatment for Multiple Sclerosis
Neurol 92:296-298, Pappolla, A.,et al, 2019
"Better Explanations" in Multiple Sclerosis Diagnostic Workup
Neurol 92:e2527-e2537, Calabrese, M.,et al, 2019
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis
JAMA Neurol 76:1446-1456, Sinnecker, T.,et al, 2019
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Maternal and Fetal Risks of Natalizumab Exposure in Utero
Neurol 90:443-444, Marrie, R.A.,et al, 2018
Value of the Central Vein Sign at 3T to Differentiate MS from Seropositive NMOSD
Neurol 90:e1183-e1190, Cortese, R.,et al, 2018
Acute acalculous cholecystitis
Neurol 90:e1548-e1552, Croteau, D.,et al, 2018
Hemophagocytic Lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab
Neurol 90:849-851, Saarela, M.,et al, 2018
Progressive multifocal leukoencephalpathy after fingolimod treatment
Neurol 90:1815-e1821, Berger, J.R.,et al, 2018